Looking at a New Treatment for Non-Small Cell Lung Cancer
NCT04928846 · RecruitingThis study looks at how well telisotuzumab vedotin works compared to docetaxel in adults with non-small cell lung cancer (NSCLC) that has already been treated. The goal is to find out if the new medicine works better and is safe for patients. Participants will receive either telisotuzumab vedotin every two weeks or docetaxel every three weeks. They will be monitored for any changes in their disease and side effects during the study.
Locations and contact
This trial is running at 317 locations. The first 8 are listed here.
- University of Alabama at Birmingham - Main /ID# 247074Birmingham, AlabamaActive, not recruiting
- Ironwood Cancer & Res Ctr /ID# 262446Chandler, ArizonaActive, not recruiting
- Mayo Clinic Arizona /ID# 255858Phoenix, ArizonaActive, not recruiting
- Onvida Health Yuma Medical Center /ID# 253625Yuma, ArizonaCompleted
- City of Hope /ID# 243157Duarte, CaliforniaRecruiting
- City Of Hope - Seacliff /ID# 263143Huntington Beach, CaliforniaRecruiting
- City of Hope - Orange County Lennar Foundation Cancer Center /ID# 263144Irvine, CaliforniaRecruiting
- City Of Hope - Antelope Valley /ID# 263138Lancaster, CaliforniaRecruiting
Who can join
Adults aged 18 and older can join. This study is for those with a specific type of lung cancer called c-Met overexpressing NSCLC. Participants should have a life expectancy of at least 12 weeks and have had no more than one previous treatment with chemotherapy. Certain gene mutations and other health conditions might affect eligibility, so the trial team will confirm who can participate.
What happens during the trial
Participants will be randomly assigned to one of two groups. One group will receive telisotuzumab vedotin every two weeks. The other group will get docetaxel every three weeks. All participants will have regular check-ups to monitor their health and any side effects they may experience.
The trial team
The trial is sponsored by AbbVie. The study director is part of AbbVie, which is responsible for overseeing the trial.
Important dates
The trial started on March 25, 2022, and is expected to finish in March 2028. It is currently enrolling new participants.
Additional information
This is a Phase 3 trial, meaning it is looking at how well these treatments work and their safety. It is regulated by the FDA, and about 698 participants are expected to join.
Other recruiting trials for the same condition, with the eligibility rules written in plain language.
Browse similar trials →Find a top oncologist who can tell you whether a trial is a sensible option for you.
Find a doctor →The cancer centers running studies like this one, and what each is known for.
Browse hospitals →